ALX Oncology Holdings Inc. reported new exploratory data showing that CD47 expression levels may help predict response to the investigational CD47 inhibitor evorpacept when used in combination with zanidatamab-hrii in patients with advanced HER2-positive metastatic breast cancer. The findings emerged from a Phase 1b/2 study evaluating the combination in heavily pretreated disease and were disclosed as part of a broader biomarker analysis submitted for presentation at an upcoming scientific meeting.

After the initial disclosure, the strategic importance of the data lies less in incremental efficacy and more in how it reframes evorpacept’s potential role within a crowded HER2-positive treatment landscape increasingly shaped by biomarker precision.

Why CD47 expression as a predictive biomarker could materially alter evorpacept’s development trajectory

The emergence of CD47 expression as a predictive biomarker represents a potentially consequential inflection point for evorpacept. CD47 biology has been extensively explored across oncology, but clinical translation has often struggled to separate responders from non-responders in a consistent and scalable way. In this context, evidence suggesting that higher CD47 expression correlates with clinical activity offers a clearer mechanistic anchor for evorpacept’s activity.

Industry observers note that the implication is not merely academic. A reproducible biomarker signal could enable ALX Oncology Holdings Inc. to refine patient selection, reduce heterogeneity in trial populations, and improve the interpretability of outcomes. In immuno-oncology programs where marginal benefit can be obscured by biological noise, such refinement can meaningfully influence development efficiency and perceived clinical value.

The fact that similar CD47-dependent patterns were previously observed in gastric cancer strengthens confidence that the signal reflects underlying biology rather than tumor-specific coincidence. Consistency across indications is often a prerequisite for biomarker credibility.

How biomarker stratification differentiates evorpacept amid an increasingly competitive HER2-positive landscape

HER2-positive metastatic breast cancer has become one of the most competitive solid tumor segments in oncology. Antibody-drug conjugates have redefined late-line expectations, compressing development timelines and raising the bar for differentiation. Against this backdrop, combination immunotherapy approaches face skepticism unless they demonstrate either superior durability or a clearly defined niche.

The evorpacept and zanidatamab-hrii combination does not attempt to replace established HER2-directed backbones. Instead, the biomarker data suggest a positioning strategy centered on biologically enriched subsets rather than broad population use. Clinicians tracking therapeutic sequencing believe this approach could support selective adoption in patients whose tumors retain both HER2 dependence and CD47-driven immune evasion.

This distinction matters because it shifts the competitive frame from direct efficacy comparisons to precision fit. If validated prospectively, CD47 expression could function as a gatekeeper biomarker, defining where evorpacept adds incremental value rather than competing head-on with dominant therapies.

What the exploratory nature of the analysis means for confidence, credibility, and clinical interpretation

Despite the promise of the findings, the exploratory design of the analysis imposes clear limitations. The Phase 1b/2 study enrolled a small number of patients, and biomarker correlations were assessed retrospectively. Regulatory and clinical audiences are likely to view the results as hypothesis-generating rather than confirmatory.

This distinction is critical for credibility. Immuno-oncology has seen multiple examples where early biomarker signals failed to replicate under prospective conditions. As a result, confidence will depend on whether upcoming trials are structured to test CD47 expression as a prespecified variable rather than a post hoc observation.

Assay reproducibility also remains an open question. CD47 expression assessment must demonstrate consistency across tumor samples, platforms, and disease stages to support clinical adoption. Without standardized testing, even a biologically sound marker may struggle to gain traction in routine practice.

How biomarker-dependent evidence thresholds could reshape regulatory expectations and late-stage trial architecture for evorpacept

From a regulatory standpoint, biomarker-driven development introduces both opportunity and complexity. Regulators generally support strategies that improve benefit-risk balance through patient selection, but such approaches require robust validation of both the biomarker and its clinical utility.

Regulatory watchers suggest that future evorpacept trials may need to incorporate CD47 expression into enrollment criteria or stratification frameworks to demonstrate prospectively that biomarker-positive patients derive disproportionate benefit. This could accelerate decision-making if results are positive, but it also raises execution risk if the signal proves less durable under controlled conditions.

The submission of full biomarker data to a scientific conference suggests an effort to expose the analysis to peer review and independent scrutiny. That process may help clarify how regulators and clinical leaders interpret the strength of the association.

defined by precision, the ability to convert exploratory biomarker signals into validated clinical tools may determine whether evorpacept secures a durable role in HER2-positive breast cancer therapy or remains a promising but limited adjunct.

How regulatory scrutiny and biomarker validation could shape evorpacept’s clinical trial design and approval pathway

From a regulatory standpoint, the emergence of CD47 expression as a potential predictive biomarker introduces both opportunity and execution risk. Regulatory watchers suggest that evorpacept’s future studies will likely need to prospectively incorporate CD47 expression into trial design, either through stratification or enrichment, to demonstrate that the biomarker meaningfully improves clinical outcomes rather than simply correlating with response retrospectively.

Such an approach could strengthen regulatory confidence if the signal holds, particularly in a late-line population where benefit-risk tradeoffs are closely examined. However, it also raises the bar for assay validation, reproducibility, and clinical utility. Regulators are likely to expect clear evidence that CD47 testing is reliable across sites and tumor samples and that it can be operationalized without introducing undue complexity or bias. Failure to meet those expectations could slow development timelines even if clinical activity remains encouraging.

What clinicians and industry observers will monitor next as evorpacept moves toward biomarker-defined positioning

Clinicians and industry observers are expected to closely track how ALX Oncology Holdings Inc. translates these exploratory findings into concrete development decisions. One of the primary questions is whether CD47 expression remains stable across successive lines of HER2-targeted therapy or whether prior treatment alters expression levels in ways that could undermine its predictive reliability. Variability over time would complicate real-world use and limit confidence in patient selection strategies.

Another area of focus will be whether CD47-driven benefit is specific to the combination with zanidatamab-hrii or reflects a broader platform effect that could extend to other HER2-targeted or immuno-oncology partners. Industry observers note that broader applicability would materially improve evorpacept’s strategic value, while partner-specific dependence could constrain scalability and commercial relevance.

There is also interest in how payers may ultimately view biomarker-restricted indications. While precision strategies can improve outcomes, they can also narrow addressable populations. Demonstrating that CD47-guided use meaningfully improves durability, resource utilization, or sequencing efficiency may be essential for long-term adoption beyond academic centers.

  ALX Oncology Holdings Inc., CD47, evorpacept, HER2-positive breast cancer, immuno-oncology, predictive biomarkers, zanidatamab-hrii